Functional neuroanatomy of the ventral striopallidal GABA pathway: New sites of intervention in the treatment of schizophrenia

Journal of Neuroscience Methods

Volumn 109, Issue 1, 2001, Pages 31-39

  O'Connor, W T ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

CCK; Neurotensin; PD13430; Pergolide; Posphodiepryl 08; Raclopride; SCH23390; SKF28293; SR48692

Indexed keywords

2 [[1 (7 CHLORO 4 QUINOLINYL) 5 (2,6 DIMETHOXYPHENYL) 3 PYRAZOLYL]CARBONYLAMINO] 2 ADAMANTANECARBOXYLIC ACID; 4 [[2 [2 [[(2 ADAMANTYLOXY)CARBONYL]AMINO] 3 (1H INDOL 3 YL) 2 METHYLPROPIONAMIDO] 1 PHENYLETHYL]AMINO] 4 OXOBUTYRIC ACID MEGLUMINE; 4 AMINOBUTYRIC ACID; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; CHOLECYSTOKININ RECEPTOR; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; DEVAZEPIDE; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR; NEUROLEPTIC AGENT; NEUROTENSIN; NEUROTENSIN RECEPTOR; NEUROTENSIN RECEPTOR ANTAGONIST; PEPTIDASE; PERGOLIDE; RACLOPRIDE; SKF 28293; UNCLASSIFIED DRUG;

AGONIST; ANIMAL EXPERIMENT; ANIMAL TISSUE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; ENZYME INHIBITION; MALE; MICRODIALYSIS; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; NONHUMAN; PERFUSION; PRIORITY JOURNAL; RAT; RECEPTOR SENSITIVITY; SCHIZOPHRENIA;

ANIMALS; CHOLECYSTOKININ; DOPAMINE; EXTRACELLULAR SPACE; GAMMA-AMINOBUTYRIC ACID; GLOBUS PALLIDUS; MALE; MICRODIALYSIS; NEURAL INHIBITION; NEURAL PATHWAYS; NEURONS; NEUROTENSIN; NUCLEUS ACCUMBENS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CHOLECYSTOKININ B; RECEPTORS, CHOLECYSTOKININ; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; RECEPTORS, NEUROTENSIN; SCHIZOPHRENIA; SYNAPTIC TRANSMISSION;

EID: 0035882488     PISSN: 01650270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-0270(01)00398-3     Document Type: Conference Paper

References (45)

1. The concentration of free amino acids and other elecrolytes in cerebrospinal fluid, in vivo dialysate of brain, and blood plasma of the dog
2. Amphetamine lowers extracellular GABA concentration in the ventral pallidum
3. Modulation of extracellualar GABA in the ventral pallidum using in vivo microdialysis
4. Two faces of cholecystokinin: Anxiety and schizophrenia
5. Neurotransmitter interactions in schizophrenia - Therapeutic implications
6. Inactivation of neurotensin by rat brain synaptic membranes partly occurs through cleavage at the Arg 8-Arg 9 peptide bond by a metalloendopeptidase
7. Cholecystokinin-dopamine interactions
8. Evidence that decreased feeding induced by systemic injection of cholecystokinin is mediated by CCK-A receptors
9. Characterization of gamma-aminobutyric acid and dopamine overflow following acute implantation of a microdialysis probe
10. Regional specific effects of clozapine and haloperidol on GABA and dopamine release in rat basal ganglia
11. Pepdidase inhibitors potentiate the effects of neurotensin and neuromedin N on self-stimulation of the medial prefrontal cortex
12. Evidence for a differential CCKB and CCKA receptor modulation of GABA release in the nucleus accumbens; possible involvement of dopaminergic and cholinergic mechanisms
13. Differential effects of intrastriatal neurotensin (1-13) and neurotensin (8-13) on striatal dopamine and pallidal GABA release. A dual-probe microdialysis study in the awake rat
14. 2 receptor regulation of rat ventral pallidal GABA levels. A dual probe microdialysis study
15. The striopallidal neuron: A main locus for adenosine-dopamine interactions in the brain
16. 2 receptors in the ventral striopallidal system. Implications for the treatment of schizophrenia
17. Adenosine-dopamine interactions in the ventral striatum. Implications for the treatment of schizophrenia
18. 2 receptors as a major mechanism for the neuroleptic-like action of neurotensin
19. Evidence for a substrate of neuronal plasticity based on pre- and postsynaptic neurotensin-dopamine receptor interactions in the neostriatum
20. Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity
21. Striatal interneurones: Chemical, physiological and morphological characterization
22. Fast estimation of GABA in microdialysis perfusates: Effects of nipecotic acid and 3-mercaptopropionic acid
23. The role of the striopallidal and extended amygdala systems in drug addiction
24. Cholecystokinin (CCK) increases GABA release in the rat anterior nucleus accumbens via CCK(B) receptors located on glutamatergic interneurons
25. Amphetamine regulation of acetylcholine and gamma-aminobutyric acid in nucleus accumbens
26. 2 receptor antagonism differentially modulates stimulation of striatal neurotransmitter levels by N-methyl-D-aspartic acid
27. Dopamine electrophysiology of ventral pallidal/substantia innominata neurons: Comparison with the dorsal globus pallidus
28. Neurotensin-dopamine interactions in the CNS
29. CCK-B receptor: Chemistry, molecular biology, biochemistry and pharmacology
30. An in vivo microdialysis characterization of extracellular dopamine and GABA in the dorsolateral striatum of halothane anaesthetized and conscious rat
31. The effects of neurotensin on GABA and acetylcholine release in the dorsal striatum of the rat: An in vivo microdialysis study
32. Differential cholinergic regulation of dopamine release in rat striatal subregions. An in vivo microdialysis study
33. Parallel processing in the basal ganglia regulation of motor function as studied by dual-probe microdialysis
34. An in vivo microdialysis characterisation of extracellular dopamine and GABA and acetylcholine in the dorsolateral striatum of awake freely moving and halothane anaesthetized rats
35. Acute versus chronic haloperidol; relationship between tolerance to catalepsy and caudate and accumbens DA, GABA and acetylcholine release
36. Comparitive localization of neurotensin receptors on nigrostriatal and mesolimbic nerve dopaminergic nerve terminals
37. 2 type receptors
38. CSF neurotensin concentrations and antipsychotic treatment in schizophrenia and schizoaffective disorder
39. Facilitation of GABA release by neurotensin is associated with a reduction in dopamine release in the nucleus accumbens
40. Cholecystokinin-B (CCKB) receptor antagonist and anxiety
41. Phosphorous containing peptides as mixed inhibitors of endopeptidase 3.4.24.15 and 3.4.24.16: Effect of neurotensin degradation in vitro and in vivo
42. 2 receptor agonists